Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Recently a dietary recommendation of 400 - 600 mg/ day has been proposed for the reduced risk of developing cardiovascular disease. Dietary flavanols can be obtained from the intake of foods such as tea, cocoa, wine, berries and apples. Incorporating Chardonnay Marc (the skins and seeds of Chardonnay grapes) into the diet can be an additional source of dietary flavanols. Like other flavanol-rich foods, Chardonnay Marc provides fiber and polysaccharides that may benefit gut health. This study seeks pilot data on the impact of the daily incorporation of Chardonnay Marc powder into the diet on markers of gut and cardiometabolic health.
The overall study objective is to obtain data on the impact of the dietary incorporation of Chardonnay marc on measures of gut and cardiometabolic health. Towards this goal, an escalation design will be employed to examine the effects of 6 - 12 weeks of daily Chardonnay marc intake on markers of gut permeability, inflammation and cardiometabolic health in obese individuals. Study procedures will be performed during 3 study visits conducted at baseline, and after 6 and 12 weeks of Chardonnay Marc intake. For each study visit, 50 ml of blood (~3.5 tbsp) will be collected. For the first six weeks of the study, the participants will be asked to incorporate 1.5 g of Chardonnay Marc into their diet between the hours of 11 am and 4 pm every day. This level of intake will be increased to 4.5 g of Chardonnay marc everyday from weeks 6-12. Therefore, all individuals will consume Chardonnay marc for at least 12 weeks. The participants will be instructed to not cook or add the Chardonnay Marc to hot foods, however, they will be allowed to add the Marc to tepid or warm foods and beverages. They will also be asked to log their intake and how they incorporated the Marc into their diet via a log.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Chardonnay Marc Intake Level 1 | Experimental | Daily intake of Chardonnay marc at 1.5 g |
|
| Chardonnay Marc Intake Level 2 | Experimental | Daily intake of Chardonnay marc at 4.5 g |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Chardonnay Marc | Other | Food product made from Chardonnay wine grapes |
|
| Measure | Description | Time Frame |
|---|---|---|
| Microvascular function | Microvascular function measured by peripheral arterial tonometry | 12 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Plasma Cholesterol | Circulating levels of plasma lipids | 12 weeks |
| Cytokines | Pro-inflammatory Th17 cytokines | 12 weeks |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Roberta R Holt, PhD | Contact | 5304005952 | rrholt@ucdavis.edu |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of California, Davis | Recruiting | Davis | California | 95616 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D002318 | Cardiovascular Diseases |
| D009765 | Obesity |
| D024821 | Metabolic Syndrome |
| ID | Term |
|---|---|
| D050177 | Overweight |
| D044343 | Overnutrition |
| D009748 | Nutrition Disorders |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
We will use a two-arm escalation design
Not provided
Not provided
Not provided
Not provided
| short chain fatty acids | Plasma and fecal levels of short chain fatty acids | 12 weeks |
| plasma bile acids | Circulating levels of primary and secondary bile acids | 12 weeks |
| blood glucose | fasting levels of blood glucose | 12 weeks |
| Gene expression | gene expression from whole blood | 12 weeks |
| insulin | plasma insulin levels after an overnight fast | 12 weeks |
| zonulin | serum and fecal zonulin as a measure of gut permeability | 12 weeks |
| lipopolysaccharide binding protein | serum measure of gut permeability | 12 weeks |
| Metabolomics | plasma levels of untargeted metabolites | 12 weeks |
| D001835 |
| Body Weight |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D007333 | Insulin Resistance |
| D006946 | Hyperinsulinism |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |